Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (Q100788540)

From Wikidata
Jump to navigation Jump to search
clinical trial
edit
Language Label Description Also known as
English
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
clinical trial

    Statements

    short name
    CONTACT-01 (English)
    0 references
    title
    A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (English)
    0 references
    sponsor
    Hoffmann-La Roche
    0 references
    country
    Australia
    0 references
    Austria
    0 references
    Belgium
    0 references
    France
    0 references
    Germany
    0 references
    Greece
    0 references
    Italy
    0 references
    Japan
    0 references
    Poland
    0 references
    Portugal
    0 references
    Spain
    0 references
    United Kingdom
    0 references
    start time
    30 September 2020
    0 references
    end time
    30 September 2022
    0 references
    number of participants
    350
    0 references
    research intervention
    docetaxel
    0 references
    atezolizumab
    0 references
    minimum age
    18 year
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q100788540&oldid=2212221154"